Eye Journal
B cells in Graves’ Orbitopathy: more than just a source of antibodies? – (B cells in Graves’ Orbitopathy: more than just a source of antibodies?, Published online: 2018-12-04; | doi:10.1038/s41433-018-0285-y)
B cells in Graves’ Orbitopathy: more than just a source of antibodies? B cells in Graves’ Orbitopathy: more than just a source of antibodies?, Published online: 04 December 2018; doi:10.1038/s41433-018-0285-y B cells in Graves’ Orbitopathy: more than just a source of antibodies?
Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy – (Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy, Published online: 2018-12-03; | doi:10.1038/s41433-018-0286-x)
Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy, Published online: 03 December 2018; doi:10.1038/s41433-018-0286-x Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy
Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy – (Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy, Published online: 2018-11-30; | doi:10.1038/s41433-018-0297-7)
Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy, Published online: 30 November 2018; doi:10.1038/s41433-018-0297-7 Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital
Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both – (Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both, Published online: 2018-11-29; | doi:10.1038/s41433-018-0280-3)
Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both Implications for pharmaceutical companies and clinicians from the <i>Bayer</i> v <i>NHS</i> judgement: an increasing budgetary focus for both, Published online: 29 November 2018; doi:10.1038/s41433-018-0280-3 Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an
Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease – (Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease, Published online: 2018-11-29; | doi:10.1038/s41433-018-0289-7)
Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease, Published online: 29 November 2018;